Creative Medical Technology Holdings Inc (CELZ)

Currency in USD
2.780
+0.030(+1.09%)
Closed·
After Hours
2.800+0.020(+0.72%)
·
CELZ Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CELZ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.7002.791
52 wk Range
1.6906.900
Key Statistics
Prev. Close
2.75
Open
2.79
Day's Range
2.7-2.791
52 wk Range
1.69-6.9
Volume
56.58K
Average Volume (3m)
112.24K
1-Year Change
-19.88%
Book Value / Share
3.12
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CELZ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.000
Upside
+619.42%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Creative Medical Technology Holdings Inc Company Profile

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, which is in IND-enabling phase, to treat infertility as a result of premature ovarian failure; iPSCelz, which is in pre-clinical stage, a platform to make cell type in the body; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson’s disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Compare CELZ to Peers and Sector

Metrics to compare
CELZ
Peers
Sector
Relationship
P/E Ratio
−1.2x−4.2x−0.5x
PEG Ratio
2.22−0.170.00
Price/Book
0.9x2.2x2.6x
Price / LTM Sales
506.9x9.7x3.2x
Upside (Analyst Target)
-65.8%43.8%
Fair Value Upside
Unlock17.9%8.1%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 20.000
(+619.42% Upside)

Earnings

Latest Release
Mar 14, 2025
EPS / Forecast
-1.87 / -1.17
Revenue / Forecast
3.00K / --
EPS Revisions
Last 90 days

CELZ Income Statement

People Also Watch

23.38
OUST
+3.96%
5.640
GVH
-5.05%
1.480
QSI
-8.64%
16.42
SRPT
-1.97%
0.858
GAME
-9.68%

FAQ

What Stock Exchange Does Creative Medical Tech Holdings Trade On?

Creative Medical Tech Holdings is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Creative Medical Tech Holdings?

The stock symbol for Creative Medical Tech Holdings is "CELZ."

What Is the Creative Medical Tech Holdings Market Cap?

As of today, Creative Medical Tech Holdings market cap is 7.10M.

What Is Creative Medical Tech Holdings's Earnings Per Share (TTM)?

The Creative Medical Tech Holdings EPS (TTM) is -3.76.

From a Technical Analysis Perspective, Is CELZ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Creative Medical Tech Holdings Stock Split?

Creative Medical Tech Holdings has split 3 times.

How Many Employees Does Creative Medical Tech Holdings Have?

Creative Medical Tech Holdings has 4 employees.

What is the current trading status of Creative Medical Tech Holdings (CELZ)?

As of 01 Aug 2025, Creative Medical Tech Holdings (CELZ) is trading at a price of 2.78, with a previous close of 2.75. The stock has fluctuated within a day range of 2.70 to 2.79, while its 52-week range spans from 1.69 to 6.90.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.